Table 2 Baseline characteristics of gastric cancer (GC) patients with and without lymph node metastasis (LNM) (n = 1580).

From: Interpretable machine learning analysis of clinicopathological and immunonutritional biomarkers for predicting lymph node metastasis in gastric cancer

Variable

Non LNM (n = 596)

LNM (n = 984)

P value

Age (years), median [IQR]

58 [51, 66]

58 [51, 65]

0.796

CEA (ug/L), median [IQR]

2.09 [1.31, 3.262]

2.53 [1.5, 5.215]

< 0.001

PT (s), median [IQR]

11.4 [10.8, 11.9]

11.5 [10.9, 12.1]

0.001

FIB (g/L), median [IQR]

2.9 [2.5, 3.47]

3.28 [2.7, 3.852]

< 0.001

PLR, median [IQR]

126.049 [96.581, 162.116]

150.188 [111.46, 203.054]

< 0.001

PNI, median [IQR]

49.6 [46.05, 53.263]

47.95 [43.95, 52.1]

< 0.001

NLR, median [IQR]

2.139 [1.523, 3.04]

2.341 [1.741, 3.289]

< 0.001

PAR, median [IQR]

48.096 [38.096, 58.928]

54.648 [43.59, 67.954]

< 0.001

RAR, median [IQR]

3.189 [2.896, 3.598]

3.363 [3.009, 3.916]

< 0.001

SIRI, median [IQR]

0.736 [0.491, 1.13]

0.845 [0.547, 1.316]

< 0.001

SII, median [IQR]

415.295 [278.044, 629.011]

533.385 [336.036, 792.912]

< 0.001

NPR, median [IQR]

0.017 [0.013, 0.023]

0.016 [0.012, 0.022]

0.009

dNLR, median [IQR]

1.627 [1.184, 2.2]

1.751 [1.325, 2.33]

0.001

MLR, median [IQR]

0.228 [0.169, 0.292]

0.241 [0.184, 0.319]

< 0.001

HRR, median [IQR]

1.107 [0.901, 1.239]

1.024 [0.75, 1.177]

< 0.001

AISI, median [IQR]

135.987 [90.154, 231.682]

190.343 [109.992, 310.939]

< 0.001

MTD (cm), median [IQR]

3 [2, 5]

5 [4, 7]

< 0.001

Gender (n, %)

 Female

134 (22.5%)

223 (22.7%)

0.984a

 Male

462 (77.5%)

761 (77.3%)

 

Location (n, %)

 Lower

315 (52.9%)

486 (49.4%)

0.401b

 Middle

150 (25.2%)

270 (27.4%)

 

 Upper

131 (22.0%)

228 (23.2%)

 

Lauren (n, %)

 Diffuse

180 (30.2%)

500 (50.8%)

< 0.001c

 Intestinal

288 (48.3%)

269 (27.3%)

 

 Mixed

128 (21.5%)

215 (21.8%)

 

Differentiation grades (n, %)

 Well

39 (6.5%)

4 (0.4%)

< 0.001d

 Moderately

253 (42.4%)

243 (24.7%)

 

 Poorly

304 (51.0%)

737 (74.9%)

 

T stage (n, %)

 T1

259 (43.5%)

30 (3.0%)

< 0.001e

 T2

118 (19.8%)

85 (8.6%)

 

 T3

54 (9.1%)

281 (28.6%)

 

 T4

165 (27.7%)

588 (59.8%)

 
  1. aFemale group as control; bUpper group as control; cIntestinal group as control; dWell group as control; eT1 stage as control. LNM, lymph node metastasis; IQR, interquartile range; CEA, carcinoembryonic antigen; PT, prothrombin time; FIB, fibrinogen; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; NLR, neutrophil-to-lymphocyte ratio; PAR, platelet-to-albumin ratio; RAR, red blood cell distribution width-to-albumin ratio; SIRI, systemic inflammatory response index; SII, systemic immune-inflammation index; NPR, neutrophil-to-platelet ratio; dNLR, derived neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; HRR, hemoglobin-to-red blood cell distribution width ratio; AISI, aggregate index of systemic inflammation; MTD, maximum tumor diameter.
Back to article page